news
Amgen wins patent block on Sanofi drug rival
Amgen has successfully blocked the manufacture, sales and marketing of its Sanofi drug rival in Germany.
List view / Grid view
Repatha (evolocumab)
news
New data adds to understanding of Repatha® (evolocumab) in multiple patient populations
23 August 2016 | By Amgen
Amgen will present data evaluating Repatha® (evolocumab) at the upcoming European Society of Cardiology (ESC) Congress 2016 in Rome...
news
NICE recommends five drugs to treat four different conditions
The National Institute for Health and Care Excellence (NICE) has published final guidance recommending that five drugs to treat four different conditions should be routinely funded by the NHS.
news
NICE recommends alirocumab and evolocumab in draft guidance
6 May 2016 | By Victoria White, Digital Content Producer
Alirocumab and evolocumab are recommended for adults with primary hypercholesterolaemia or mixed dyslipidaemia...
news
Positive topline results from GAUSS-3 trial of Repatha
5 February 2016 | By Victoria White
The Phase 3 GAUSS-3 trial evaluating Amgen’s Repatha (evolocumab) in patients with high cholesterol who cannot tolerate statins met its co-primary endpoints...
news
NICE says ‘no’ to Amgen’s Repatha in draft guidance
18 November 2015 | By Victoria White
The NICE Committee felt the question whether Repatha (evolocumab) would reduce angina, heart attacks and strokes remains unanswered...
news
FDA approves LDL cholesterol drug Repatha
28 August 2015 | By Victoria White
Repatha, the second drug approved in a new class of drugs known as PCSK9 inhibitors, has been approved by the FDA for some patients who are unable to get their LDL cholesterol under control with current treatment options...
news
EC approves Amgen’s cholesterol-lowering medication Repatha
21 July 2015 | By Victoria White
The EC has granted marketing authorisation for Repatha for the treatment of patients with uncontrolled cholesterol who require additional LDL-C reduction...
news
Amgen receives positive CHMP opinion for use of Repatha for the treatment of high cholesterol
22 May 2015 | By Victoria White
The CHMP has adopted a positive opinion for the marketing authorisation of Amgen’s Repatha for use in certain patients with high cholesterol...
news
FDA to review Amgen’s Repatha as a treatment for high cholesterol
30 April 2015 | By Victoria White
The FDA will review data supporting Amgen’s Biologics License Application (BLA) for Repatha (evolocumab) for the treatment of high cholesterol...
news
Thomson Reuters names most promising drugs of 2015
24 March 2015 | By Victoria White
The Intellectual Property and Science business of Thomson Reuters has released the 2015 edition of its annual Drugs to Watch report...
news
Amgen presents long-term data showing efficacy and safety of investigational cholesterol-lowering medication evolocumab across lipid And LDL-C levels
Amgen (NASDAQ:AMGN) has announced new data from three separate analyses of Phase 2 and 3 studies evaluating evolocumab, a novel investigational low-density lipoprotein cholesterol (LDL-C)-lowering medication.
news
Biologics to Complement Statins in Cholesterol Treatment Space, says GlobalData Analyst
12 November 2014 | By GlobalData
Biologics will play an influential role in shaping the future of cardiovascular (CV) drug treatment, as these and other emerging therapies will compete for patients who cannot tolerate statins, or for whom statin therapy alone is insufficient, according to an analyst with research and consulting firm GlobalData...
news
Amgen announces positive top-line results from Phase 3 YUKAWA-2 trial of evolocumab
28 August 2014 | By Amgen
...in combination with statins in Japanese patients with high cardiovascular risk and high cholesterol.
news
New detailed Phase 3 data show Amgen’s novel investigational cholesterol-lowering medication evolocumab significantly reduced LDL Cholesterol
2 June 2014 | By Amgen
...in patients with a rare and serious genetic disorder that causes high cholesterol.
